ARTICLE | Company News

Xoma rises on Novartis deal

October 2, 2015 12:58 AM UTC

Xoma Corp. (NASDAQ:XOMA) gained $0.33 (44%) to $1.08 on Thursday after it granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to its antibody program targeting transforming growth factor-beta (TGFB).

The deal includes preclinical candidate XOMA 089, a mAb targeting TGFB1 and TGFB2. Novartis spokesperson Jeffrey Lockwood declined to disclose the indications the company will pursue for XOMA 089. In July, Xoma said it hoped to out-license the compound for development in immuno-oncology and fibrosis. ...